logo
What you need to know about Ontario's summer health risks

What you need to know about Ontario's summer health risks

CTV News7 hours ago
A man kayaks in Lake Ontario on a warm sunny day in Toronto on Friday, August 19, 2016. THE CANADIAN PRESS/Nathan Denette
As Ontario enters peak summer season, infectious disease experts are warning that some viruses — from respiratory bugs to mosquito-borne illnesses — thrive in the heat.
While many people may consider winter to be the season when they are most at risk of catching a virus and becoming ill, experts who spoke to CTV News Toronto said that there are many infections that actually peak in the summer.
Dr. David Fisman, a professor of epidemiology at the University of Toronto's Dalla Lana School of Public Health, said that respiratory infections like rhinovirus, enterovirus and para-influenza are all more common in the summer months and are capable of causing mild illness.
He also said that other more serious health threats, like measles, can 'come back' when people make a decision to skip vaccination.
Ontario reported fewer new measles cases this past week; 33 compared to 96 the week before, officials say the outbreak now stands at 2,212 cases since October.
'If we were having this conversation 100 years ago, we would be talking in a time when in Toronto, summertime was the high mortality season, and most of that mortality was from infectious diseases,' Fisman said, emphasizing that deaths have gone down thanks to smart public health measures.
Does climate change play a role?
Mosquitoes and ticks are another concern as climate change expands their reach across Canada.
Dr. Isaac Bogoch, an infectious diseases specialist at Toronto General Hospital, said Lyme disease is already well established in many parts of Canada.
Why Lyme disease is on the rise
Dr. Isaac Bogoch explains why Lyme disease is on the rise.
'We do see a fair bit of Lyme in Canada. In 2024 there were roughly 5,000 cases that were identified, but that's likely a gross underestimate. We're probably not detecting the majority of cases. So people should be aware that Lyme is out there,' he said. 'It's very easy to prevent Lyme infections… people can just be mindful where ticks live, typically in tall grass or in forested areas, you can wear insect repellent to reduce the risk of a tick bite, and it's certainly helpful to do tick checks.'
To check if ticks or reported Lyme disease has been reported in your area, the Public Health Agency of Canada has created a free online portal where residents can enter their postal code or the first three letters of their city.
Travelling this summer?
Bogoch also warned that international travellers should prepare for serious infections not found in Canada.
'Mosquito avoidance is key with insect repellent,' he said. 'For infections like malaria, many people should be taking tablets to prevent this infection. It can be very severe and even deadly, and it's important that people are aware that malaria is out there.'
'It's a really good idea to get professional travel advice,' he added. 'There might be infections in other parts of the world that we just don't see in Canada, and these are largely preventable.'
Malaria
Malaria death rates have been in steady decline since 2000 but rose in 2016 as progress towards eliminating the mosquito-borne preventable disease stalled. (Ales_Utovko / istockphoto.com)
Fisman echoed those warnings, noting that hotter climates accelerate mosquito activity.
'Mosquitoes bite more when it's hotter, their biting rate increases and when you have diseases like dengue or yellow fever or chikungunya… that all gets speeded up and outbreaks can happen,' he said.
Hotter weather 'can increase' foodborne illnesses
While some people associate summer illness with food poisoning or stomach bugs, Fisman said the risks are 'climate sensitive.'
'There are foodborne illnesses like Campylobacter, Shigella and salmonella… and those are climate sensitive,' he said. 'Hotter weather can increase the risk of foodborne illness, obviously increase the risk of food spoilage and so forth.'
He also noted the growing concern around antibiotic resistance, pointing to new Canadian research: 'My colleague Dr. Derek MacFadden, at University of Ottawa, has actually shown that hotter weather is associated with a surge in antibiotic resistance, which people may not realize.'
How to stay healthy?
Experts say basic hygiene still matters, especially when it comes to respiratory viruses.
'The advice in terms of respiratory infections is the advice for COVID,' said Fisman. 'If you're in a closed, crowded space, you can open a window. You can do activities outdoors if you're concerned. You (should not) show up and infect other people if you're sick.'
Bogoch agreed the risks are manageable — if people stay informed.
'Enteroviruses are more common in the summer months, and to no one's surprise, we're starting to see a rise in reported enterovirus cases in Canada,' he said.
But he wants to reassure people there is no reason to sound the alarm.
'The key message is, have a wonderful summer. Enjoy. We're going to be okay.'
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures
REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

National Post

time3 hours ago

  • National Post

REPEAT/Cybin Announces Financing of up to US$500 Million Aggregate Principal Amount of Convertible Debentures

Article content Article content – Funding agreement contemplates a conversion formula with a potential 30% premium upon conversion and positions the Company for growth, and accelerated advancement of its clinical pipeline programs, CYB003 and CYB004 – Article content Article content TORONTO — Cybin Inc. (NYSE American: CYBN) (Cboe Canada: CYBN) (' Cybin ' or the ' Company '), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, is pleased to announce the Company has entered into a securities purchase agreement (the ' Securities Purchase Agreement ') with High Trail Special Situations LLC (' High Trail '), pursuant to which the Company agreed to sell and issue to High Trail up to US$500,000,000 in aggregate principal amount of unsecured convertible debentures (the ' Convertible Debentures '). The sale and issue of US$50,000,000 principal amount of Convertible Debentures was completed on June 30, 2025 (the ' Private Placement '). The sale and issue of US$450,000,000 of the principal amount of Convertible Debentures will be determined at a future date, upon mutual agreement of the parties. Article content 'This financing represents a major inflection point for Cybin and supports our position as a leader within our sector,' said Doug Drysdale, Chief Executive Officer of Cybin. 'High Trail Capital is an experienced investor, and its confidence and appreciation of our breakthrough clinical data and intellectual property portfolio recognize the potential of the Company. This financing comes at an opportune time for Cybin, as we advance our lead programs, CYB003 and CYB004, in Phase 3 and Phase 2, respectively. CYB003 demonstrated over 70% remission rates and continued durability over 12 months for patients with uncontrolled depression. We await the conclusion of our CYB004 Phase 2 proof-of-concept study, in patients with generalized anxiety disorder,' said Drysdale. Article content Joseph Gunnar & Co., LLC acted as the sole placement agent in connection with this transaction. Article content Pipeline Acceleration Drives Multiple Value Creation Catalysts Article content The funding will accelerate Cybin's clinical-stage programs across multiple high-value indications: Article content CYB003 Program Achievements: Article content Breakthrough Clinical Results: Unprecedented 71% remission rate in major depressive disorder at 12 months after two 16 mg doses in Phase 2 study Durability advantage: 12-month sustained efficacy demonstrating long-term therapeutic benefit FDA Recognition: Breakthrough Therapy Designation received, expediting regulatory pathway Multinational Phase 3 PARADIGM program underway Article content CYB004 Program Momentum: Article content Dual Indication Strategy: Expanding addressable market opportunity Phase 2 GAD study expected to complete around mid-year 2025 1 Article content Commercialization Infrastructure: Article content Value Catalysts Drive Sustained Momentum Article content Near-Term Catalysts: Article content CYB004 Phase 2 GAD study expected to complete around mid-2025 1 Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025 1 EXTEND study initiation imminent 1 Article content Medium-Term Catalysts (2025-2026): Article content Transaction Terms Article content The Convertible Debentures have a two-year term from the closing date (the ' Term '). The Company shall pay guaranteed interest equal to 5.5% of the principal per annum for the Term. Such interest was pre-paid on closing. Upon the occurrence of an event of default, interest shall increase to a rate of 18% per annum on the outstanding principal balance. Pursuant to the terms of the Securities Purchase Agreement, the Company and High Trail may, upon mutual consent, enter into subsequent securities purchase agreements for the purchase and sale of up to an additional US$450,000,000 principal amount of Convertible Debentures, in tranches, in amounts on such dates as may be mutually agreed and each subsequent tranche shall include prepaid interest at a rate of 9.5%. Article content Subject to the terms of the Securities Purchase Agreement and the Convertible Debentures, High Trail will be entitled to convert the principal amount of, and accrued and unpaid interest, if any, on each Convertible Debenture, in whole or in part, from time to time, into common shares in the capital of the Company (the ' Common Shares ') at a conversion price per Common Share equal to the lower of (a) 130% of the volume weighted average price (' VWAP ') of the Common Shares on the day prior to the initial issuance of the Convertible Debentures, or (b) the VWAP of the Common Shares during the five trading days immediately prior to the date of conversion. Article content The Company, in its sole discretion, may prepay any outstanding amount under the Convertible Debentures, in whole or in part, in cash by providing High Trail with advance written notice prior to such prepayment. The prepayment shall include, (i) if paid during the first year after closing, a 5% prepayment premium on the amount of the prepayment or (ii) if paid thereafter, a 3% prepayment premium on the amount of the prepayment. Article content The terms of the Convertible Debentures restrict the conversion of Convertible Debentures by High Trail if such a conversion or exercise would cause High Trail, together with any affiliate thereof, to beneficially own in excess of 4.99% of the number of Common Shares outstanding immediately after giving effect to such conversion. Article content The Company intends to use the net proceeds from the Private Placement for working capital and general corporate purposes. Article content The Convertible Debentures were offered on a private placement basis pursuant to prospectus exemptions in Canada and pursuant to exemptions and exclusions from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws. The Company has agreed to use commercially reasonable efforts to: (a) file a prospectus supplement to the Company's base shelf prospectus dated August 17, 2023, as amended on December 22, 2023, April 8, 2024 and January 6, 2025, with applicable Canadian securities regulators to qualify the secondary market sales of the Common Shares in the United States; and (b) either (i) prepare and file the Canadian prospectus supplement with the United States Securities and Exchange Commission, or (ii) file a prospectus supplement pursuant to General Instruction II.L of Form F-10 with the United States Securities and Exchange Commission to the Company's registration statement on Form F-10 (File No. 333-284173), which was declared effective by the SEC on January 14, 2025, or on such other form as may be available to the Company, in either case qualifying the resale of the Common Shares underlying the Convertible Debentures. Article content No securities regulatory authority has either approved or disapproved of the contents of this news release. This news release is not an offer to sell or the solicitation of an offer to buy the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification or registration under the securities laws of such jurisdiction. The securities being offered have not been registered under the U.S. Securities Act, and such securities may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons absent registration or an applicable exemption from U.S. registration requirements and applicable U.S. state securities laws Article content About Cybin Article content Cybin is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions. Article content With promising proof-of-concept data, Cybin is working to change the mental health treatment landscape through the introduction of intermittent treatments that provide long lasting results. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds. Article content Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom, the Netherlands and Ireland. For Company updates and to learn more about Cybin, visit or follow the team on X, LinkedIn, YouTube and Instagram. Article content There is no assurance that timelines will be met. Anticipated timelines regarding the initiation, advancement and results of clinical trials are based on reasonable assumptions informed by current knowledge and information available to the Company. See 'Cautionary Notes and Forward-Looking Statements'. Article content Cautionary Notes and Forward-Looking Statements Article content Certain statements in this news release constitute forward-looking information and forward-looking statements within the meaning of applicable securities laws (together, 'forward-looking statements'). Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements. These statements generally can be identified by the use of forward-looking words such as 'may', 'should', 'could', 'intend', 'estimate', 'plan', 'anticipate', 'expect', 'believe' or 'continue', or the negative thereof or similar variations. Forward-looking statements in this news release include statements regarding the use of Private Placement proceeds; the conversion of the Convertible Debentures into Common Shares; the sale and issue of US$450,000,000 principal amount of Convertible Debentures at a future date; CYB004 Phase 2 GAD study expected to complete around mid-2025; Initiation of second CYB003 pivotal study, EMBRACE, around mid-2025; the Company's Medium-Term Catalysts for 2025-2026; Phase 3 PARADIGM program enrollment acceleration; the Company's ability to achieve commercial success; and the Company's ability to address the need for new and innovative treatment options for people who suffer from mental health conditions. Article content These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the psychedelics market; the ability of the Company to successfully achieve its business objectives; plans for growth; political, social and environmental uncertainties; employee relations; the presence of laws and regulations that may impose restrictions in the markets where the Company operates; implications of disease outbreaks on the Company's operations; and the risk factors set out in each of the Company's management's discussion and analysis for the three and nine month periods ended December 31, 2024 and the Company's annual information form for the year ended March 31, 2024, which are available under the Company's profile on and with the SEC on EDGAR at Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law. Article content Cybin makes no medical, treatment or health benefit claims about Cybin's proposed products. The U.S. Food and Drug Administration, Health Canada or other similar regulatory authorities have not evaluated claims regarding psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds. The efficacy of such products has not been confirmed by approved research. There is no assurance that the use of psilocin, psychedelic tryptamine, tryptamine derivatives or other psychedelic compounds can diagnose, treat, cure or prevent any disease or condition. Rigorous scientific research and clinical trials are needed. If Cybin cannot obtain the approvals or research necessary to commercialize its business, it may have a material adverse effect on Cybin's performance and operations. Article content Article content Article content Article content Article content Contacts Article content Investor & Media Contact Article content : Article content

Synaptive Medical Secures Strategic Investment to Accelerate Growth and Innovation
Synaptive Medical Secures Strategic Investment to Accelerate Growth and Innovation

National Post

time4 hours ago

  • National Post

Synaptive Medical Secures Strategic Investment to Accelerate Growth and Innovation

Article content MedTech leader emerges from restructuring with renewed momentum and an unwavering focus on transformative surgical care. Article content TORONTO — Synaptive Medical, a global medical technology innovator, today announced the successful completion of a strategic restructuring and the closing of a significant new private investment. This milestone marks a pivotal new chapter for the company—one that strengthens its mission to revolutionize neurosurgical care in close collaboration with clinicians worldwide. Article content 'We remain deeply committed to investing in the people, tools, and technologies that drive progress in surgical planning, neuro-navigation, robotic exoscopy, and advanced MRI,' said Cameron Piron, President and Founder of Synaptive Medical. 'From enhancing surgical precision with our integrated robotic and navigation systems to expanding the diagnostic potential of our MRI platforms, Synaptive is redefining the future of surgery—from imaging to intervention.' Article content As part of its transformation, Synaptive is reaffirming its commitment to its comprehensive product portfolio. The company will continue to expand its integrated surgical suite—including Modus X™, Modus Nav™, and Modus Plan™ —alongside its dedicated MRI platform. These advancements are closely aligned with long-standing partnerships at leading hospitals and clinical institutions around the world. Article content Throughout the restructuring, Synaptive maintained uninterrupted customer support while continuing to execute on its innovation roadmap. Recent milestones include major software upgrades across its platforms and the launch of new collaborations with internationally recognized medical centers in the United States and Europe. Article content The newly secured investment will bring the company to profitability and reflects strong confidence in Synaptive's strategic direction and long-term growth. The company has been wholly acquired by a mission-aligned consortium of MedTech executives, clinicians, and experienced investors who bring deep domain expertise and a shared vision for the future of neurosurgical care. Article content 'This investment represents a powerful recommitment to Synaptive's mission: to transform brain health in the 21st century for patients and families in need,' said Dr. Joshua Bernstock, neurosurgeon and incoming board member. 'We're proud to join forces with a team that is not only passionate about elevating the standard of care but also fearless in pushing the boundaries of what's possible in diagnostics and surgical innovation.' Article content This investment represents the first phase of a broader capital initiative, with additional funding expected in the coming weeks to further support Synaptive's growth strategy and accelerate its innovation pipeline. Article content About Synaptive Medical Article content Synaptive Medical Inc. is a Toronto-based global medical technology company dedicated to solving complex challenges in surgery, imaging, and data integration to improve patient outcomes. Its integrated suite of solutions—spanning MRI, surgical planning, navigation, and robotic visualization—delivers intelligent, patient-centric technology that enhances clinical decision-making and efficiency across every stage of neurosurgical care. Article content Article content Article content Article content Article content Contacts Article content Media: Article content Article content Article content

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store